The effect of CYP2C19 polymorphism on Japanese patients simultaneously receiving calcineurin inhibitor and voriconazole post hematopoietic stem cell transplant

The effect of CYP2C19 polymorphism on Japanese patients simultaneously receiving calcineurin inhibitor and voriconazole post hematopoietic stem cell transplant - The effect of CYP2C19 polymorphism on VRCZ metabolism

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010863

Enrollment

Registered

2013-06-03

Start date

2013-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematopoietic diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age over 20-years-old and less than 65-years-old at the time of obtaining informed consent 2) Patients scheduled to use calcineurin inhibitors 3) Patients who have given written informed consent before stem cell transplant

Exclusion criteria

Exclusion criteria: 1) Patients with allergic reaction to calcineurin inhibitors or voriconazole 2) Any other patient, whom the treating physician has declared inappropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of CYP2C19 polymorphism on the blood concentration level of calcineurin inhibitors and voriconazole	—

Countries

Japan

Contacts

Public ContactYuya Kohda

Keio University School of Medicine Division of Hematology

koukouda@gmail.com+81-3-3353-1211

Outcome results